Safety of 2 Recombinant Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Vaccines in Neonates Born to HIV-1-Infected Women
Coleen K. Cunningham(Duke Medical Center), William Borkowsky(New York University), Anne‐Marie Duliège(Sunesis (United States)), Terry Fenton(Harvard University), Donald Francis(SUNY Upstate Medical University), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Minhee Kang(Cancer Research And Biostatistics), D. W. Wara(University of California, San Francisco), Elizabeth Hawkins(SUNY Upstate Medical University), James McNamara(National Institute of Allergy and Infectious Diseases), Elizabeth J. McFarland(University of Colorado Anschutz Medical Campus)
Cited by 75
Related Papers
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|896
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|697